Your Article Summary
See Latest ArticlesCutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib
British Journal of Dermatology, 06/25/09
Lee MW et al. - Multitargeted kinase inhibitors are associated with a significant risk of various cutaneous adverse events. HFSR is the commonest and most serious cutaneous toxicity in patients treated with these drugs.
Related Articles
Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer
British Journal of Cancer, 10/19/09
Relevance Score: 89%
Phase I/II study of sunitinib malate in Japanese patients with gastrointestinal stromal tumor after failure of prior treatment with imatinib mesylate
Investigational New Drugs, 10/08/09
Relevance Score: 88%
Electrocardiographic Characterization of the QTc Interval in Patients with Advanced Solid Tumors: Pharmacokinetic- Pharmacodynamic Evaluation of Sunitinib
Clinical Cancer Research, 11/16/09
Relevance Score: 87%
Recovery of paraneoplastic hypercalcemia by sunitinib treatment for renal cell carcinoma: a case report and review of the literature
Medical Oncology, 10/23/09
Relevance Score: 87%
Identification of TNF-alpha and MMP-9 as potential baseline predictive serum markers of sunitinib activity in patients with renal cell carcinoma using a human cytokine array
British Journal of Cancer, 11/13/09
Relevance Score: 84%
Today in Adverse Drug Reactions...keeping you current
Receive free subspecialty "5-minute updates" via email
Continuation of Low-Dose Aspirin in Peptic Ulcer Bleeding. A Randomized Trial
Annals of Internal Medicine, 12/01/09
Activated prothrombin complex concentrate factor VIII inhibitor bypassing activity (FEIBA) for the reversal of warfarin-induced coagulopathy
International Journal of Emergency Medicine, 12/01/09
Seliciclib in malignancies
Expert Opinion on Investigational Drugs, 11/30/09